Today is a monumental day for Strand Therapeutics!
We are beyond thrilled to announce that we have dosed our first patient with STX-001 in the company's first clinical trial! This groundbreaking therapy promises to induce deep anti-tumor immune responses and prevent cancer recurrence with minimal systemic exposure of the drug in solid tumor patients.
A heartfelt thank you to the patients signing up for this trial - your fight against cancer is our inspiration.
A huge shoutout to our incredible world renowned investigators for running this trial and to every single Strand employee - from discovery, preclinical, manufacturing, clinical, G&A, and to our advisors - your dedication made this possible.
Gratitude also goes out to our investors and partners for believing in our vision, and to the funding agencies and academic collaborators who supported our research journey from MIT to Strand.
For me, this journey began 12 years ago when I first started programming mRNA in the lab, and today, seeing it administered to our first patient is nothing short of a dream come true.
This is just the beginning, and I can’t wait to see the positive impact we will make on countless lives. Let’s transform patient care together!
Join us at ASCO for more insights on our trial design and the future of cancer therapy.
Presentation Date/Time: 6/1/2024 9:00AM-12:00PM CDT
Location: McCormick Place, Chicago, Illinois, Hall A
Poster Board Number: 161b
Permanent Abstract Number: TPS2696
Read our press release: https://lnkd.in/g-j9vq6v
#Programmable #mRNA #Oncology #ClinicalTrials #FirstPatientDosed #ASCO24 #ASCO2024
Today is an exciting day of firsts for Strand Therapeutics. We are proud to announce the dosing of our first patient with STX-001 in our first Phase 1 trial for the treatment of cancer patients with solid tumors. STX-001 represents the first-ever programmable mRNA therapy to enter clinical trials.
STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment.
Join us at ASCO for more information on the trial design:
Presentation Date/Time: 6/1/2024 9:00AM-12:00PM CDT
Title: A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors.
Session: Developmental Therapeutics -- Immunotherapy
Location: McCormick Place, Chicago, Illinois, Hall A
Poster Board Number: 161b
Permanent Abstract Number: TPS2696
Read our press release: https://lnkd.in/g-j9vq6v
#Programmable #mRNA #Oncology #ClinicalTrials #FirstPatientDosed #ASCO24 #ASCO2024
Strand Therapeutics Announces First Patient Dosed with Programmable mRNA Therapy STX-001 in Phase 1 Trial for Solid Tumors
businesswire.com
Congratulations on this significant milestone, Strand Therapeutics! The dosing of your first patient with STX-001 marks a pivotal moment in cancer treatment research. Your innovative approach with programmable mRNA therapy opens new avenues for addressing solid tumors.